Redefining Treatment in the $8B Sleep Apnoea Market

We are tackling the $8B global sleep apnoea burden affecting over 67M people annually.

Our flagship device offers a simpler, more comfortable alternative to CPAP and mandibular systems, with early trials showing a 73% reduction in apnoea events, exceeding FDA efficacy thresholds.

With CE/TGA approvals, 5 patents, and tooling complete, we’re commencing a 30-patient clinical trial led by a world-recognised sleep medicine expert with over 150 peer-reviewed publications.